1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
DIO Corporation

DIO Corporation

KKRX:039840
10,080.00
KRW
-320.00
(-3.08%)
535.22EPS
27.06P/E
214.72BMarket Cap
Nov 17Next Earn
DIO Corporation
KRX:039840
(Korea Stock Exchange)

Recent

price

10,080.00

P/E

ratio

27.06

div

yld

1.21%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
4,046.52
4,413.74
4,732.95
5,905.48
5,789.92
5,964.67
6,050
6,389.99
6,325.91
8,677.61
8,159.83
10,259.22
8,857.47
10,681.56
8,296.12
12,033.97
12,534.79
Revenue per Share
-541
433.32
-197
-572
-160
895
1,410
595
379
1,483
758
1,932
-1,380
227
-2,865
-100
602.33
Basic EPS, GAAP
-769.53
171.88
185.4
-582.99
-148.34
1,007.08
72.65
-722.46
-518.39
-607.46
336.96
-1,046.07
-914.18
-42.42
716.64
850.27
554.93
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
78.59
- -
- -
61.39
- -
- -
72.8
120.54
121.47
Dividend per Share
4,952.27
4,391.66
4,201.08
3,666.41
4,015.72
5,561.89
7,181.21
7,514.64
7,738.11
9,524.1
10,823.89
12,628.79
11,250.15
13,386.16
14,657.28
14,551.26
14,367.88
Book Value per Share
4,461.82
3,849.74
3,939.57
3,554.82
3,932.06
5,519.76
7,150.91
7,414.8
7,468.63
8,598.47
9,801.61
11,483.11
10,447
12,632.13
14,536.5
14,383.53
14,202
Tangible Book Value per Share
13
12
11
11
11
12
15
14
14
15
15
15
15
15
14
14
14
Basic Weighted Avg Shares
51,198
51,256
53,360
66,831
65,366
73,485
88,020
91,918
91,043
127,165
120,056
150,037
131,306
155,818
119,650
164,078
169,595
Sales/Revenue/Turnover
2.2
17.54
16.91
-1.2
8.37
29.76
30.22
23.98
8.88
27.34
24.99
23.19
-3.36
13.41
-34.05
6.16
7.5
Operating Margin (%)
1,412
1,534
1,641
1,877
2,318
2,218
2,879
4,040
5,844
8,840
9,543
11,417
13,170
12,309
11,238
9,377
9,498
Depreciation Expense
-6,845
5,032
-2,221
-6,473
-1,806
11,026
20,514
8,559
5,455
21,732
11,153
28,255
-20,458
3,311
-41,320
-1,363
8,150
Net Income, GAAP
- -
- -
- -
- -
- -
26.84
18.12
28.27
- -
27.68
30.83
16.83
- -
74.83
- -
- -
- -
Effective Tax Rate (%)
-13.37
9.82
-4.16
-9.69
-2.76
15.01
23.31
9.31
5.99
17.09
9.29
18.83
-15.58
2.13
-34.53
-0.83
4.81
Profit Margin (%)
45,791
48,668
35,809
39,427
-6,669
47,713
55,729
51,054
51,521
49,329
51,918
60,698
19,629
11,822
51,565
46,275
57,595
Working Capital
35,121
37,704
40,747
45,620
- -
14,625
2,547
12,970
25,502
16,590
17,979
13,997
8,597
3,984
18,265
28,207
39,496
LT Debt
59,038
49,478
47,524
41,601
45,454
81,095
110,200
114,785
119,285
143,652
161,866
187,541
167,252
194,427
204,114
191,683
189,267
Total Equity
- -
- -
- -
- -
- -
16.73
20.18
12.18
- -
13.87
8.93
10.61
- -
1.9
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
15.38
18.99
6.32
- -
10.33
5.43
11.16
- -
1.99
- -
- -
- -
Return on Capital (%)
-13.04
9.27
-4.58
-14.55
-4.16
17.41
21.82
7.88
4.87
16.97
7.37
16.27
-11.6
1.84
-20.74
-0.69
4.15
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
52,723
52,712
43,682
LT Borrowings
25,130
25,125
35,120
LT Finance Leases
3,063
3,082
4,376
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
13
13
13
Market Capitalization
233,639
222,491
214,719

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
160,825
152,969
153,929
Cash, Cash Equivalents & STI
44,440
48,018
44,110
Accounts Receivable, Net
77,894
68,267
72,611
Inventories
27,004
26,220
26,869
Total Current Liabilities
106,853
106,694
96,335
Payables & Accruals
- -
- -
- -
ST Debt
52,723
52,712
43,682
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.73%
4.04%
-6.09%
Free Cash Flow
-361.3%
-454.73%
12.17%
Net Income, GAAP
-133.85%
-315.95%
-96.7%
Sales/Revenue/Turnover
10.24%
9.02%
37.13%
Total Cash Common Dividend
- -
- -
56.52%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
34,964
15,540
31,346
37,801
119,650
2025
35,805
40,099
41,449
46,725
164,078
2026
41,323
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
290
-3,259
-493
644.25
-2,865
2025
8
-642.73
438.55
113.83
-100
2026
720.7
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
35.72
- -
- -
37.7
72.8
2025
4.72
37.83
38.91
39.21
120.54
2026
5.13
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
Medtronic plc. (NYSE:MDT)
Business
DIO Corporation (039840.KQ) manufactures and sells dental implants, digital dental solutions, and related medical devices primarily in South Korea and internationally; it also provides parking systems and steel structures for buildings. Founded in 1988 and headquartered in Busan, South Korea, the company operates through its medical equipment division, which offers core implant systems including UFII internal submerged and non-submerged types, FTN external systems, Protem implants, UV Active implant systems with vacuum UV surface treatment for enhanced osseointegration, and hybrid surface treatment technologies; digital dentistry products such as the PROBO 3D printer, DIO NAVI flapless guide system, full arch rehabilitation solutions, and orthodontic tools like DIO ORTHOnavi; additional dental lasers, surgical instruments, whitening foam toothpastes, children's foam toothpastes, foam cleansers, and cardiovascular medical devices; as well as its parking system division serving domestic and export markets. The company maintains production facilities and sales networks across more than 12 countries, including joint ventures in India and subsidiaries in China and Mexico, targeting dentists, clinics, and healthcare providers globally. In recent developments, DIO launched the UFIII implant system in select regions during 2025 following its earlier introduction in Korea, continues workforce and management restructuring initiated in 2023-2024 to strengthen financial soundness by reducing receivables and debt while expanding export sales networks, and announced an equity buyback program in May 2025 that expired after repurchasing 3.89% of shares for approximately KRW 10 billion.